BDC and Living Cell will collaboratively pursue regulatory approval and then conduct a US clinical trial in type 1 diabetes with DiabeCell, Living Cell’s encapsulated porcine insulin producing cells. The proposed US trial is planned to commence in 2009 and will be planned utilizing the clinical protocols and results from Living Cell’s trials in Russia and New Zealand.
Paul Tan, CEO of Living Cell Technologies, said: “We are pleased to have the extensive clinical trial capability of experts from one of the most established diabetes centers in the US to help us get DiabeCell to people with diabetes.”